In Vivo is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Bristol And AstraZeneca Make A Splash In Diabetes With Joint Purchase Of Amylin

Executive Summary

Bristol-Myers’ and AstraZeneca’s deal to acquire Amylin Pharmaceuticals for $7 billion, announced June 29, reaffirms the partners’ commitment to the vast and growing type 2 diabetes market, even if the competition is intense and the companies’ five-year-old alliance got off to a rocky start.


Related Content

AstraZeneca’s Seasoned Dealmaker Grady On Strategy To Grow Pipeline
AstraZeneca, Flying Solo, Sees Momentum Take Off In Diabetes
In A Changing Diabetes Drug Market, Who Will Come Out On Top?
With Bristol/AstraZeneca In Driver’s Seat, GLP-1 Race Takes A Turn
AstraZeneca/BMS's Dapagliflozin Needs European Epidemiological Study, But Headed For Strong Label
Weeks After Bydureon Launch, Amylin Looks Like A Takeout Target
Amylin’s Bydureon Approval: How Does It Sit With Novo Nordisk?
With Bydureon’s U.S. Approval, Amylin Extends Exenatide Franchise
In Deal With BI, Lilly Gets Late-Stage Diabetes Drugs
BMS Deals Diabetes Drugs, Solidifies Specialist Stance


Related Companies

Related Deals




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts